Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

INTRODUCTION: Resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies is an emerging clinical problem. The efficacy of anti-EGFR therapies can be influenced by the presence of heregulins (HRGs), which can bind erbB3/4 receptors and can activate alternative signalling pathways. In t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hutcheson, Iain R, Knowlden, Janice M, Hiscox, Steve E, Barrow, Denise, Gee, Julia MW, Robertson, John F, Ellis, Ian O, Nicholson, Robert I
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2007
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2206726/
https://ncbi.nlm.nih.gov/pubmed/17686159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr1754
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados